PSA Velocity
So, basically: Your PSA number, by itself, means Jack. What happens to it over time means everything This is called PSA velocity - Janet Worthington

image by: HWN
HWN Suggests
Controversy Over PSA Velocity: Does It Indicate Prostate Cancer?
While higher PSA values have tended to correlate with the presence of prostate cancer, it reveals nothing about the localization, extent or aggressiveness of the tumors. PSA blood testing continues to prevail as a signal of prostate bioactivity, but its merit has been called into question with increasing forcefulness. Researchers, recognizing the value of advanced imaging—particularly multiparametric MRI—to provide pictorial information before recommending biopsy are increasingly advocating a larger role for scans. Even as new blood or urine tests eclipse PSA and PSAV, mpMRI will be an essential component of prostate cancer workups.
Articles of Interest
PSA velocity in prostate cancer screening—the debate continues
Prostate cancer screening in the PSA era is controversial and the most appropriate measures for diagnosis are widely debated. Vickers and colleagues recently suggested that using PSA velocity in screening offers little benefit compared with traditional markers; however, elimination of this test from practice or guidelines may be premature.
Prostate-specific antigen (PSA) velocity: a test of controversial benefit in the era of increased prostate cancer screening
The current study suggests that PSAV is not as beneficial a screening test as previously believed; however, that does not mean that PSAV should be disregarded altogether. By their own estimates, using PSAV would help diagnose more cancer and more aggressive cancer.
Prostate-Specific Antigen Trends Predict the Probability of Prostate Cancer in a Very Large U.S. Veterans Affairs Cohort
In the evolving prostate cancer screening paradigm using new technologies, PSA is the low-cost way to begin screening a population of men. PSA trends may help identify men at elevated risk who could be referred for further evaluation, even at low to moderate PSA levels.
PSA Velocity Does Not Improve Prostate Cancer Detection
A rapid increase in prostate-specific antigen (PSA) levels is not grounds for automatically recommending a prostate biopsy... “Overall, PSA velocity did not importantly add predictive accuracy to a standard predictive model or to just PSA alone,” wrote Andrew Vickers, Ph.D., and his colleagues from Memorial Sloan-Kettering Cancer Center (MSKCC). “We found no reason to believe that implementation of the guideline would improve patient outcomes; indeed, its use would lead to a large number of unnecessary biopsies.”
PSA velocity prostate screening may lead to unnecessary biopsies
In an accompanying editorial, Siu-Long Yao, M.D., and Grace Lu-Yao, Ph.D., of the Cancer Institute of New Jersey agree that the findings suggest that PSA velocity does not help doctors and patients decide what to do about screening results. "PSA velocity measurements take time to acquire, and recognizing that such data add relatively little information may help prevent inappropriate postponement of follow-up in affected patients," they write. "Avoiding the wait to acquire subsequent PSA values may also help reduce some of the anxiety associated with testing." They go on to say that the results of this study serve to "remind us that the use of PSA as a screening tool still leaves much to be desired."
PSA Velocity Risk Count Helps Identify Clinically Significant Prostate Cancer
PSA risk count is only feasible with men who have a serial PSA history, but many men present with a lengthy PSA history of prior values. PSA risk count makes a baseline PSA and annual PSA testing two essential practices. When the PSA history is available, this study shows that risk count has a robust association with prostate cancer risk, and especially high-grade disease.
PSA velocity: A systematic review of clinical applications
The value of prostate-specific antigen (PSA) for screening and management of prostate cancer (CaP) continues to engender much controversy in the medical and lay literature.
Why PSA Is a Trend, Not One Number
Schematic diagram...

